| Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation KM Sakamoto, KB Kim, A Kumagai, F Mercurio, CM Crews, RJ Deshaies Proceedings of the National Academy of Sciences 98 (15), 8554-8559, 2001 | 1807 | 2001 |
| The ubiquitin‐proteasome pathway and proteasome inhibitors J Myung, KB Kim, CM Crews Medicinal research reviews 21 (4), 245-273, 2001 | 619 | 2001 |
| Crystal structure of epoxomicin: 20S proteasome reveals a molecular basis for selectivity of alpha', beta'-epoxyketone proteasome inhibitors M Groll, KB Kim, N Kairies, R Huber, CM Crews Journal of the American Chemical Society 122 (6), 1237-1238, 2000 | 402 | 2000 |
| Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation KM Sakamoto, KB Kim, R Verma, A Ransick, B Stein, CM Crews, ... Molecular & Cellular Proteomics 2 (12), 1350-1358, 2003 | 396 | 2003 |
| Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro IR Garrett, D Chen, G Gutierrez, M Zhao, A Escobedo, G Rossini, ... Journal of Clinical Investigation 111 (11), 1771-1782, 2003 | 368 | 2003 |
| The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin P Bargagna-Mohan, A Hamza, Y Kim, Y Khuan Abby Ho, N Mor-Vaknin, ... Chemistry & biology 14 (6), 623-634, 2007 | 361 | 2007 |
| Total synthesis of the-potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology N Sin, KB Kim, M Elofsson, L Meng, H Auth, BHB Kwok, CM Crews Bioorganic & medicinal chemistry letters 9 (15), 2283-2288, 1999 | 272 | 1999 |
| cGAS drives noncanonical-inflammasome activation in age-related macular degeneration N Kerur, S Fukuda, D Banerjee, Y Kim, D Fu, I Apicella, A Varshney, ... Nature medicine 24 (1), 50-61, 2018 | 226 | 2018 |
| Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer A Rodriguez-Gonzalez, K Cyrus, M Salcius, K Kim, CM Crews, ... Oncogene 27 (57), 7201-7211, 2008 | 217 | 2008 |
| Impact of linker length on the activity of PROTACs M Wehenkel, EY Choi, HJ Han, H Lee, H Swanson, KB Kim Molecular BioSystems 7 (2), 359-364, 2011 | 200* | 2011 |
| From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes K BoáKim Natural product reports 30 (5), 600-604, 2013 | 183 | 2013 |
| Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency KB Kim, J Myung, N Sin, CM Crews Bioorganic & medicinal chemistry letters 9 (23), 3335-3340, 1999 | 154 | 1999 |
| Lack of proteasome active site allostery as revealed by subunit-specific inhibitors J Myung, KB Kim, K Lindsten, NP Dantuma, CM Crews Molecular cell 7 (2), 411-420, 2001 | 148 | 2001 |
| LMP2-specific inhibitors: chemical genetic tools for proteasome biology YKA Ho, P Bargagna-Mohan, M Wehenkel, R Mohan, KB Kim Chemistry & biology 14 (4), 419-430, 2007 | 146 | 2007 |
| The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up-or down-regulate antigen presentation at nontoxic doses K Schwarz, R de Giuli, G Schmidtke, S Kostka, M van den Broek, KB Kim, ... The Journal of Immunology 164 (12), 6147-6157, 2000 | 130 | 2000 |
| Next-generation proteasome inhibitors for cancer therapy JE Park, Z Miller, Y Jun, W Lee, KB Kim Translational Research 198, 1-16, 2018 | 124 | 2018 |
| Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes G de Bruin, EM Huber, BT Xin, EJ van Rooden, K Al-Ayed, KB Kim, ... Journal of medicinal chemistry 57 (14), 6197-6209, 2014 | 120 | 2014 |
| Inhibitors of the immunoproteasome: current status and future directions Z Miller, L Ao, K Bo Kim, W Lee Current pharmaceutical design 19 (22), 4140-4151, 2013 | 117 | 2013 |
| Development of an aryl hydrocarbon receptor antagonist using the proteolysis-targeting chimeric molecules approach: a potential tool for chemoprevention D Puppala, H Lee, KB Kim, HI Swanson Molecular pharmacology 73 (4), 1064-1071, 2008 | 108 | 2008 |
| Jostling for Position: Optimizing Linker Location in the Design of Estrogen Receptor‐Targeting PROTACs K Cyrus, M Wehenkel, EY Choi, H Lee, H Swanson, KB Kim ChemMedChem 5 (7), 979-985, 2010 | 100 | 2010 |
